NuPathe to Present at Upcoming Investor Conferences
MarketwirePress Release: NuPathe Inc. – 19 hours ago
hopeful for continued rally into it
CONSHOHOCKEN, PA--(Marketwire -02/07/12)- NuPathe Inc. (NASDAQ: PATH - News), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Jane Hollingsworth, chief executive officer, will present company overviews at two upcoming investor conferences.
On Tuesday, February 14, 2012, NuPathe will present at the 14th Annual BIO CEO & Investor Conference at 3:00 p.m. EST. The conference is being held at The Waldorf Astoria Hotel in New York, NY.
On Wednesday, February 15, 2012, NuPathe will present at the Leerink Swann 2012 Global Healthcare Conference at 4:00 p.m. EST. The conference is also being held at The Waldorf Astoria Hotel in New York, NY.
Live audio webcasts of the presentations will be available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. Replays of the webcasts will also be archived on NuPathe's website for 90 days following the presentation.
About NuPathe
NuPathe Inc. (www.nupathe.com) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.
Contact:
Contact Information:
John Woolford
Westwicke Partners, LLC
(443) 213-0506
john.woolford@westwicke.com
Keith A. Goldan
Vice President & Chief Financial Officer
NuPathe Inc.
(484) 567-0130
MarketwirePress Release: NuPathe Inc. – 19 hours ago
hopeful for continued rally into it
CONSHOHOCKEN, PA--(Marketwire -02/07/12)- NuPathe Inc. (NASDAQ: PATH - News), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Jane Hollingsworth, chief executive officer, will present company overviews at two upcoming investor conferences.
On Tuesday, February 14, 2012, NuPathe will present at the 14th Annual BIO CEO & Investor Conference at 3:00 p.m. EST. The conference is being held at The Waldorf Astoria Hotel in New York, NY.
On Wednesday, February 15, 2012, NuPathe will present at the Leerink Swann 2012 Global Healthcare Conference at 4:00 p.m. EST. The conference is also being held at The Waldorf Astoria Hotel in New York, NY.
Live audio webcasts of the presentations will be available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. Replays of the webcasts will also be archived on NuPathe's website for 90 days following the presentation.
About NuPathe
NuPathe Inc. (www.nupathe.com) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.
Contact:
Contact Information:
John Woolford
Westwicke Partners, LLC
(443) 213-0506
john.woolford@westwicke.com
Keith A. Goldan
Vice President & Chief Financial Officer
NuPathe Inc.
(484) 567-0130
Recent PATH News
- UiPath Celebrates Five-Year Listing Anniversary at NYSE • PR Newswire (US) • 04/21/2026 12:55:00 PM
- UiPath Celebrates Five-Year Listing Anniversary at NYSE • PR Newswire (Canada) • 04/21/2026 12:55:00 PM
- UiPath Celebrates Five-Year Listing Anniversary at NYSE • PR Newswire (US) • 04/21/2026 12:55:00 PM
- UiPath Leadership to Ring Opening Bell at New York Stock Exchange to Mark Five-Year IPO Anniversary • Business Wire • 04/20/2026 08:30:00 PM
- UiPath Announces AI-Powered Orchestration and CX Automation on Salesforce AgentExchange • Business Wire • 04/16/2026 12:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:26:30 PM
- UiPath to Showcase Latest Agentic Business Orchestration Capabilities and Product Strategy in Upcoming Webinar • Business Wire • 03/31/2026 08:10:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/27/2026 05:52:27 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/25/2026 09:06:48 PM
- UiPath Announces New Agentic Solution to Accelerate Procurement Cycles • Business Wire • 03/25/2026 12:51:00 PM
- UiPath Optimizes Retail and Manufacturing Operations with New Agentic Solutions • Business Wire • 03/25/2026 12:48:00 PM
- UiPath Launches Agentic Solutions to Strengthen Fraud Prevention and Accelerate Lending • Business Wire • 03/25/2026 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 12:31:39 PM
- UiPath Chief Technology Officer Raghu Malpani Takes Expanded Role as Chief Product and Technology Officer • Business Wire • 03/25/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 12:04:07 AM
- UiPath Collaborates with Microsoft to Accelerate Security and Confidence for Automated Workflows • Business Wire • 03/18/2026 12:30:00 PM
- UiPath Expands Strategic Alliance with Deloitte to Launch Agentic ERP • Business Wire • 03/12/2026 08:30:00 PM
- UiPath Announces Rescheduled Fourth Quarter and Year-end Earnings Conference Call Q&A Session • Business Wire • 03/11/2026 10:19:00 PM
- UiPath Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results • Business Wire • 03/11/2026 08:10:00 PM
- UiPath Achieves AIUC-1 Certification, Setting New Standard for AI Agent Security and Reliability • Business Wire • 03/09/2026 08:30:00 PM
- UiPath Joins Agentic AI Foundation (AAIF) to Advance Interoperability in Agentic AI Adoption • Business Wire • 02/24/2026 09:30:00 PM
- UiPath Launches Agentic AI Solutions to Break Administrative & Financial Bottlenecks for Clinicians and Healthcare Admins • Business Wire • 02/23/2026 01:30:00 PM
- CORRECTING and REPLACING UiPath Named to G2’s 2026 Best Software Awards in Five Categories • Business Wire • 02/18/2026 10:18:00 PM
- UiPath Named to G2’s 2026 Best Software Awards in Five Categories • Business Wire • 02/18/2026 09:30:00 PM

